Table 1.
Neutralization, binding, and ADCC of therapeutic mAbs against Delta, BA.2 BA.4, and BA.5
| Neutralization, IC50 (ng/ML) |
Binding, EC50 (ng/mL) |
ADCC, AUC |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Delta | BA.2 | BA.4 | BA.5 | Delta | BA.2 | BA.4/5 | Delta | BA.2 | BA.4/5 | |
| Sotrovimab | 64.18 | >9,000 | 996 | 1,088 | 72.3 | 1,429 | 848.2 | 11.1 | 5.7 | 6.4 |
| Cilgavimab | 7.9 | 6.1 | 6.5 | 11 | 22 | 39 | 49.3 | 0.1 | 0.2 | 0.2 |
| Tixagevimab | 1.6 | >9,000 | >9,000 | >9,000 | 7.8 | 4,226 | >9,000 | 0.2 | 0.2 | 0.1 |
| Evusheld (cilgavimab/tixagevimab) | 2.5 | 24.7 | 26.1 | 22.6 | 13.5 | 72.9 | 92.3 | 0.2 | 0.4 | 0.1 |
| Bebtelovimab | 3.8 | 4.5 | 1.3 | 2 | 12.2 | 20.2 | 17.4 | 1.6 | 1.6 | 2.1 |
| Casirivimab | 1.3 | >9,000 | >9,000 | >9,000 | 11.1 | >9,000 | >9,000 | 0.9 | 0.3 | 0.2 |
| Imdevimab | 2.4 | 1,120 | 265 | 208 | 12.8 | 610 | 391 | 5.4 | 3.2 | 3.9 |
| Ronapreve (imdevimab/casirivimab) | 2 | 1,985 | 660 | 700 | 12.8 | 1,106 | 739 | 5.2 | 2.6 | 3.2 |